1. Management of CMV in HSCT Recipients

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. CMV: A Common Infection After HSCT

5. CMV: Most Clinically Significant Viral Infection in HSCT Recipients in the Era of Preemptive Therapy

6. Risk Factors for CMV Reactivation

7. CMV Serostatus: A Key Consideration in High-Risk Patients

8. CMV Management Strategies

9. Preemptive Therapy: Unmet Needs

10. CMV Prevention in HSCT Recipients: What's in the Pipeline?

11. Primary Letermovir Prophylaxis in High-Risk Patients

12. Primary Letermovir Prophylaxis in High-Risk Patients (cont)

13. SUPPRESS Primary Brincidofovir Prophylaxis in High-Risk Patients

14. Brincidofovir: The AdVise Trial Treatment of Adenovirus

15. Maribavir Treatment of Resistant/Refractory Infections in HSCT and SOT Recipients

16. Adoptive T-Cell Transfer Restoring Cellular Immunity in the Recipient

17. CMV Vaccines: The Future of CMV Prevention?

18. Anti-CMV Combination mAb Restoring Humoral Immunity in the Recipient

19. Concluding Remarks

20. Abbreviations